The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.

Viruses, including corona viruses such as COVID-19, are often present in the mouth or nose of a person before they infect the body. The disclosed electrochemical device destroys or denatures viruses in the mouth or nose rendering the viruses ineffective to cause infection by applying a low voltage potential to the mucus. The device can being configured to detect viruses through chronoamperomatry.

A rapid testing mechanism for respiratory viral pathogens includes a filter material positioned to capture exhaled breath particles from a respiratory tract. At least a portion of the filter material includes a pathogen binding adsorptive reagent, wherein the pathogen binding adsorptive reagent is a sulfated cellulose membrane. When the exhaled breath particles pass through the filter material, the following occur: when the binding adsorptive reagent reacts, a positive test for respiratory viral pathogens is indicated by the filter material; and when the pathogen binding adsorptive reagent does not react, a negative test for respiratory viral pathogens is individuated by the filter material.

The present invention relates to a system capable of performing simple and rapid inspection of an antigen equivalent to the immune chromatographic method with accuracy good as a PCR method. An embodiment relates to a novel fluorescence counting system for quantifying viruses or antibodies in an analyte which comprises an unit of providing an antigen or antibody phase solidified substrate by an aggregation method with quantum crystals, an unit for making a labeling liquor and labeling a virus or an antibody to be measured in the analyte by an antigen-antibody method, an unit of exciting the fluorescently labeled virus or antibody by a surface plasmon excitation method, and an unit of counting fluorescent points in an excited fluorescent screen to quantify the virus or antibody in the analyte.

Disclosed herein is a recombinant antibody against the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A kit containing the recombinant antibody for use in coronavirus detection is encompassed in the present disclosure. Also disclosed herein are in vitro methods of detecting coronavirus infection in a subject with the aid of the recombinant antibody.

Saliva-based testing for viruses including SARS-CoV-2 are provided. Simple collection methods allow for at-home collection, reducing the risk and burden on healthcare workers using conventional testing methods. Tests can quantitatively analyze both viral nucleic acids to assess viral load as well as virus-specific antibodies to track disease progression and potential immunity.

Provided herein is a SARS-CoV-2 coronavirus nucleocapsid (N) protein, where the N protein is substantially free of RNA. Also provided are methods of using the N protein including methods for inducing anti-N protein antibody in a subject, treating an infection, and detecting the presence or absence of anti-N protein antibody.

This disclosure relates to portable devices for SARS-COV-2 Antigen (SC2A), a biomarker for the detection of Coronavirus disease 2019 (COVID19). Diagnosis of viral infections such as SARS-COV-2 can be obtained in the early stages of a disease by detection of viral antigens (e.g., SC2A) directly in the clinical specimen.

The present disclosure relates to methods and compositions, e.g., kits, for quantitatively detecting an antibody of a subject to an infectious organism. In some embodiments, the present disclosure provides for methods and compositions, e.g., kits, for quantitatively detecting a human antibody to SARS-CoV-2 polypeptide or S (spike) polypeptide. Certain applications and uses of the present methods and compositions, e.g., kits, are also provided.

The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.